Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety Assessment of Ex-Vivo Expanded Allogeneic γδT Cells in Hepatocellular Carcinoma Patients in Phase 1 Clinical Trial

NCT04518774 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT04518774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04518774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety Assessment of Ex-Vivo Expanded Allogeneic γδT Cells in Hepatocellular Carcinoma Patients in Phase 1 Clinical Trial
Lead sponsor
Beijing 302 Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 15, 2020
Completion date
August 15, 2021
Enrollment
8 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma